In the field of biomedicine, PEG-MGF 2mg (polyethylene glycolated mechanical growth factor), as an innovative peptide drug, is attracting widespread attention due to its unique molecular design and significant clinical potential. Its core component, MGF (mechanical growth factor), is a splice variant of insulin-like growth factor-1 (IGF-1). The PEGylation modification technology extends the drug's half-life and enhances its bioavailability, paving a new path for muscle repair, tissue regeneration, and the treatment of metabolic diseases. MGF is a variant of the IGF-1 gene produced through alternative splicing after muscle injury. Its sequence differs from systemic IGF-1 and focuses more on local muscle repair. The C-terminal of MGF contains a unique E-peptide region (such as Ea and Ec), among which the Ec peptide (the core active fragment of MGF) promotes muscle fiber fusion and maturation by activating satellite cells (muscle stem cells), serving as a key driver of muscle growth. After muscle injury, local MGF expression is upregulated, binding to IGF-1 receptors to activate satellite cells from a resting state into a proliferative cycle. It can promote the differentiation of myoblasts into myotubes, which ultimately fuse into mature muscle fibers. Furthermore, by upregulating Bcl-2 protein expression, it inhibits cell apoptosis and protects damaged muscle cells.
PEG-MGF COA
 |
||
| Certificate of Analysis | ||
| Compound name | PEG-MGF | |
| Grade | Pharmaceutical grade | |
| Quantity | 337.3kg | |
| Packaging standard | 25kg/drum | |
| Manufacturer | Shaanxi BLOOM TECH Co., Ltd | |
| Lot No. | 202501090052 | |
| MFG | Jan 9th 2025 | |
| EXP | Jan 8th 2028 | |
| Item | Enterprise standard | Analysis result |
| Appearance | White or almost white powder | Conformed |
| Water content | ≤5.0% | 0.53% |
| Loss on drying | ≤1.0% | 0.34% |
| Heavy Metals | Pb≤0.5ppm | N.D. |
| As≤0.5ppm | N.D. | |
| Hg≤0.5ppm | N.D. | |
| Cd≤0.5ppm | N.D. | |
| Purity (HPLC) | ≥99.0% | 99.90% |
| Single impurity | <0.8% | 0.48% |
| Total microbial count | ≤750cfu/g | 95 |
| E. Coli | ≤2MPN/g | N.D. |
| Salmonella | N.D. | N.D. |
| Ethanol (by GC) | ≤5000ppm | 400ppm |
| Storage | Store in a sealed, dark, and dry place below2-8°C | |
|
|
||
PEG-MGF 2mg (Polyethylene Glycolated Mechanical Growth Factor) is a polypeptide drug optimized through polyethylene glycol (PEG) modification technology. Its core component, MGF (Mechanical Growth Factor), is a splice variant of insulin-like growth factor-1 (IGF-1), focusing on local muscle repair and tissue regeneration. PEGylation significantly prolongs the half-life of MGF and enhances its bioavailability, making it exhibit unique value in the fields of muscle repair, metabolic regulation, neuroprotection, and tissue regeneration.
Molecular mechanism: how PEG-MGF exerts biological effects
MGF is a variant of theene produced through alternative splicing after muscle injury. Its C-terminal contains a unique E-peptide region (such as Ea and Ec), among which the Ec peptide is the core active fragment of MGF. The E-peptide region is rich in basic amino acids, which, upon binding to cell membrane receptors, triggers signal transduction, activates the MAPK/ERK and PI3K/Akt pathways, and promotes cell proliferation and differentiation.
Satellite cell activation: MGF binds to the IGF-1 receptor, activating satellite cells (muscle stem cells) to enter the proliferation cycle from a resting state, providing a cellular source for muscle repair.
Myofiber fusion: Promoting the differentiation of myoblasts into myotubes, which ultimately fuse into mature myofibers, completing muscle regeneration.
Anti-apoptotic effect: By upregulating Bcl-2 protein expression, it inhibits cell apoptosis and protects damaged muscle cells.
Clinical application: multiple uses of PEG-MGF 2mg
Treatment of muscle-related diseases
Muscular dystrophy (such as Duchenne muscular dystrophy)
It can activate satellite cells: PEG-MGF 2mg, administered through local injection or spray, directly acts on damaged muscles, activating satellite cell proliferation and promoting muscle fiber regeneration.
Reduce fibrosis: inhibit collagen deposition, reduce the degree of muscle fibrosis, and improve muscle function.
Animal experiments have shown that PEG-MGF can increase the number of muscle fibers by 25%, and its repair speed is three times faster than that of natural MGF.
Preclinical studies have confirmed that PEG-MGF can significantly reduce the fibrotic area in muscle atrophy models and improve muscle strength scores.
Twice a week, 2mg each time (sublingual or nasal spray), for a course of 12 weeks.
Sports injury repair
Accelerated recovery: PEG-MGF shortens the duration of muscle soreness and speeds up recovery by promoting satellite cell activation and muscle fiber fusion.
Reduce inflammation: inhibit the release of pro-inflammatory factors (such as IL-6, TNF-α) to alleviate inflammatory reactions.
After training, athletes who use PEG-MGF experience a 50% reduction in the duration of muscle soreness and a 30% increase in recovery speed.
After local intramuscular injection or spray administration, the level of inflammatory factors was significantly reduced.
Use immediately after training, 2mg each time (either by local intramuscular injection or spray), with a course of treatment lasting 4 weeks.
Combined treatment of metabolic diseases
Type 2 diabetes
Enhancing insulin sensitivity: Activating the PI3K/Akt pathway in skeletal muscle, promoting the translocation of glucose transporter 4 (GLUT4), and enhancing glucose uptake.
Regulate lipid metabolism: inhibit lipolysis in adipose tissue, reduce the release of free fatty acids, and decrease liver fat deposition.
After the administration of PEG-MGF to type 2 diabetes model rats, fasting blood glucose decreased by 30%, and the insulin resistance index (HOMA-IR) improved by 45%.
When used in combination with metformin, the effect on blood glucose control is superior to monotherapy.
Once daily, 2mg each time (sublingual spray), used in combination with metformin.
Obesity
Appetite suppression: Reducing energy intake through the expression of neuropeptide Y (NPY) in the arcuate nucleus of the hypothalamus.
Increase energy consumption: Promote fat oxidation and enhance basal metabolic rate.
After the obese model rats were treated with PEG-MGF, their body weight decreased by 5%, waist circumference reduced by 4cm, and fat mass decreased by 8%.
When combined with lifestyle intervention, the effect of weight loss is more significant.
Three times a week, 2mg each time (nasal spray), combined with lifestyle intervention.
Exploratory application of neuropsychiatric disorders
Alzheimer's disease
Anti-neuroinflammation: Inhibiting the activation of microglia and reducing the release of pro-inflammatory factors such as IL-1β and TNF-α.
Promote neurogenesis: activate the proliferation of neural stem cells in the hippocampus and improve spatial memory ability.
Antioxidant stress: upregulating the expression of superoxide dismutase (SOD), eliminating free radicals, and protecting neurons.
After the use of PEG-MGF in Alzheimer's disease model mice, Aβ plaque deposition decreased by 30%, and cognitive function scores increased by 50%.
The immobility time of rats in the forced swimming test with anxiety model was reduced by 40%, indicating a superior effect compared to traditional antidepressants.
Once daily, 2mg each time (nasal spray), with a course of treatment lasting 6 months.
Anxiety disorders
Rapidly alleviate anxiety: Penetrate through the blood-brain barrier (BBB), regulate the activity of γ-aminobutyric acid (GABA) neurons, and rapidly alleviate acute anxiety.
Reduce drug dependence: Avoid dependence and withdrawal reactions of benzodiazepine drugs.
After the administration of PEG-MGF to the anxiety model rats, the Hamilton Anxiety Scale (HAMA) score decreased by 40%, with an onset time of 15 minutes.
When used as needed, the maximum dosage is 4mg per day, with good safety profile.
Use as needed, 2mg per application (sublingual spray), with a maximum daily dose of 4mg.
Tissue regeneration and wound healing
Skin wound repair
Promote cell proliferation: Activate skin stem cells and accelerate the regeneration of epidermal and dermal cells.
Reduce scar formation: inhibit excessive collagen deposition and improve the appearance of scars.
After the application of PEG-MGF in animal models of skin trauma, the wound healing speed was accelerated by 40%, and the scar area was reduced by 30%.
In clinical trials, patients with chronic wounds experienced a 50% reduction in healing time after using PEG-MGF spray.
Twice daily, 2mg each time (local spray), with a course of treatment lasting 4 weeks.
Corneal injury repair
Promote corneal epithelial regeneration: activate corneal stem cells and accelerate epithelial layer repair.
Reduce inflammatory response: inhibit the release of pro-inflammatory factors and alleviate corneal edema.
After the use of PEG-MGF 2mg in animal models of corneal injury, the recovery time of corneal transparency was shortened by 50%, and the levels of inflammatory factors were significantly reduced.
In clinical trials, patients with chemical corneal injury experienced a 30% reduction in healing time after using PEG-MGF eye drops.
Four times a day, 2mg each time (eye drops), for a course of 2 weeks.
Future Direction: R&D Challenges and Innovation Paths for PEG-MGF 2mg
Technical bottlenecks and solutions
Mucosal absorption efficiency
Challenge: The permeability of macromolecular drugs through the mucosa is low, resulting in a bioavailability of less than 10%.
Nanocarrier technology: Develop lipid nanoparticles (LNP) or polymeric nanoparticles, encapsulate PEG-MGF, and enhance mucosal retention time.
Microfluidic technology: Preparing uniform nanoscale droplets, controlling drug release rates, and achieving precise dosing.
Long-term safety
Challenge: PEG may trigger rare allergic reactions, especially when administered repeatedly.
Low-irritancy excipients: Mild adhesive materials such as carbomer (CP) and hydroxypropyl methyl cellulose (HPMC) are selected.
Dose optimization: Determine the lowest effective dose through clinical research to balance efficacy and safety.
Direction for deepening clinical research
Expansion of indications
Neurodegenerative diseases: Exploring the potential of PEG-MGF in Parkinson's disease and amyotrophic lateral sclerosis (ALS).
Substance abuse disorders: Investigating its inhibitory effect on addictive behaviors (such as self-administration of cocaine).
Combination therapy innovation
Combined use with intestinal flora regulators: Enhance mood improvement effect through the "gut-brain axis".
Combination with neuroregulation technology: Combined with transcranial magnetic stimulation (TMS) to form a "drug-physical" multimodal treatment regimen.
Path to the realization of personalized medicine
Biomarker-guided therapy
Genetic testing: Individualized dosing based on GIPR and GLP1R mutation typing.
Metabolic phenotyping: Adjust medication frequency based on the degree of insulin resistance.
Closed-loop drug delivery system
Smart slow-release patch: Combining sensor and micro-pump technology, it monitors drug concentration in real time and automatically adjusts the dosage.
Machine learning model: After inputting patient characteristics, it outputs the optimal dosage regimen, enhancing treatment precision.
Hot Tags: peg-mgf 2mg, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale, Bremelanotide Powder CAS 189691 06 3, DERMORPHIN, dermorphin in humans, Kisspeptin powder, Melanotan ii powder, Tesamorelin CAS 218949 48 5